Cardiac allograft vasculopathy prevention
|
Cardiac allograft vasculopathy Microchapters |
|
Differentiating Cardiac allograft vasculopathy from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Cardiac allograft vasculopathy prevention On the Web |
|
American Roentgen Ray Society Images of Cardiac allograft vasculopathy prevention |
|
Directions to Hospitals Treating Cardiac allograft vasculopathy |
|
Risk calculators and risk factors for Cardiac allograft vasculopathy prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2] Raviteja Guddeti, M.B.B.S. [3]
Overview
Prevention
As the pathogenesis of CAV consists of both immunological and non-immunological insults, it has been suggested that preventative strategies should consist of control of risk factors for CAV and optimal immunosuppressive therapy. However, the best preventative strategy to delay development of CAV is yet to be determined.
Optimization of Immunosuppressive Therapy
The rapamycin derivatives, sirolimus and everolimus, have been proven to have significant benefit in the prevention of CAV in addition to statins. Other options for immunosuppressive therapy include [1]:
Everolimus and Sirolimus
- Act by inhibiting mTOR (mammalian target), thereby having anti-proliferative effects in response to allo-antigens.
- Everolimus is currently not FDA approved for clinical use in the United States.
- Associated with significantly reduced incidence of graft rejection.
- Serial IVUS studies to evaluate intimal proliferation demonstrated smaller increase in maximal intimal thickness and intimal index in patients taking everolimus [2]. Similar results were found in trials that studied sirolimus [3].
- Side effect profile:
- Everolimus: increase in serum creatinine levels, hyperlipidemia, anemia, thrombocytopenia, peripheral edema, hypertension. However, opportunistic viral infections less often seen.
- Sirolimus: Similar to everolimus, however recent reports of impaired wound healing have been reported in renal transplant patients.
Mycophenolate mofetil
- Studies have shown trend towards a lower maximal intimal thickness on IVUS, lower incidence of retransplantation and death with mycophenolate when compared to azathioprine [4].
- Side effect profile: chest pain, hypertension/hypotension, tachycardia, peripheral edema, headache, fever, rash, abdominal pain, nausea, diarrhea/constipation, leukopenia, anemia, thrombocytopenia, liver function test abnormalities, abnormal creatinine and BUN, increased risk for infections
Calcineurin inhibitors
- The use of calcineurin inhibitors i.e cyclosporin and tacrolimus have not been shown to lower the risk of developing CAV.
- This suggests that other immunological pathways may exists that play a role in the pathogenesis of CAV. Moreover, side effects from use of these drugs leads to a high incidence of not only chronic renal disease but also hypertension and hyperlipidemia which in turn may accelerate the process of CAV.
Non-Immunosuppressive therapy
Non-immunosuppressive therapy includes:
- Lipid lowering therapy with statins
- Anti-hypertensive medications to optimize blood pressure
- Optimal glucose control in diabetic patients
- Anti-cytomegalovirus therapy
- Antioxidants
Statins
- Obesity, elevated levels of cyclosporine, use of steroids and insulin resistance all contribute to the development of hyperlipidemia in cardiac transplant patients. Use of statins have proven to reduce mortality in multiple randomized controlled trials.
- Immunomodulatory effects of statins include:
- Inhibition of smooth muscle proliferation
- By inhibiting lipid production, statins halt the intra-cellular signal transduction and consequently protein synthesis
- By inhibiting expression of genes for growth factors essential for proliferation of smooth muscles
- Direct influence on gene expression of endothelin-1, leading to improved endothelial function thereby protecting against atherogenesis.
- Prevents attachment of monocytes to endothelium, which is the first step in atherogenesis [5]
- In the presence of immunosuppressants like cyclosporin A, statins reduce natural killer cell activity, T cell proliferation and activity in vitro. Moreover, statin induced LDL receptor activation leads to increase in intracellularly available LDL-bound cyclosporin A [6].
- Inhibition of smooth muscle proliferation
- The effects of simvastatin over a period of 8 years was studied in a randomized controlled trial by Wenke and colleagues [5] in which the study group received simvastatin on the fourth post-operative day, whereas the control group was managed with dietary therapy alone. At the end of 8 years, the Kaplan-Meier survival rate was 88.6% in the simvastatin group versus 59.5% in the control group (P< 0.006 by log rank, HR 0.24,95% CI, 0.08-0.71). The incidence of transplant vasculopathy was also found to be lower in the simvastatin group compared to the control group.
References
- ↑ Mehra MR (2006). "Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy". Am J Transplant. 6 (6): 1248–56. doi:10.1111/j.1600-6143.2006.01314.x. PMID 16686747.
- ↑ Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler HA; et al. (2003). "Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients". N Engl J Med. 349 (9): 847–58. doi:10.1056/NEJMoa022171. PMID 12944570.
- ↑ Matsuo Y, Cassar A, Yoshino S, Flammer AJ, Li J, Gulati R; et al. (2013). "Attenuation of cardiac allograft vasculopathy by sirolimus: Relationship to time interval after heart transplantation". J Heart Lung Transplant. 32 (8): 784–91. doi:10.1016/j.healun.2013.05.015. PMC 3727915. PMID 23856215.
- ↑ Eisen HJ, Kobashigawa J, Keogh A, Bourge R, Renlund D, Mentzer R; et al. (2005). "Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients". J Heart Lung Transplant. 24 (5): 517–25. doi:10.1016/j.healun.2005.02.002. PMID 15896747.
- ↑ 5.0 5.1 Wenke K, Meiser B, Thiery J, Nagel D, von Scheidt W, Krobot K; et al. (2003). "Simvastatin initiated early after heart transplantation: 8-year prospective experience". Circulation. 107 (1): 93–7. PMID 12515749.
- ↑ Kurakata S, Kada M, Shimada Y, Komai T, Nomoto K (1996). "Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro". Immunopharmacology. 34 (1): 51–61. PMID 8880225.